Core Insights - The 8th China International Import Expo has opened in Shanghai, with Johnson & Johnson showcasing its commitment to addressing global health challenges through innovative medical technologies [1][2] - Johnson & Johnson's latest pulse field ablation (PFA) solutions have garnered significant attention, including the debut of the OMNYPULSE catheter, which quantifies ablation damage depth and provides real-time pressure monitoring [1] - The VARIPULSE catheter, launched in April, has already served over 2,000 patients, demonstrating its potential in treating atrial fibrillation [1] Group 1 - Johnson & Johnson emphasizes its comprehensive strength across medical technology and innovative pharmaceuticals at the expo [1] - The company aims to introduce a new PFA product to the Chinese market annually, enhancing atrial fibrillation treatment standards [2] - The DESTSF catheter combines radiofrequency and pulse energy, showcasing advanced capabilities in real-time pressure and ablation index monitoring [1] Group 2 - The immersive "healing space" created by Johnson & Johnson at the expo highlights its dedication to innovation in healthcare [1] - The introduction of the OMNYPULSE catheter marks a significant advancement in the field of pulse ablation technology [1] - Johnson & Johnson's ongoing commitment to innovation is reflected in its strategic focus on the Chinese market [2]

Core Viewpoint - Jianhu Medical Technology (Suzhou) Co., Ltd. has developed the StarTrek cardiac electrophysiology three-dimensional mapping system, which has received the Class III medical device registration certificate from the state, marking a significant advancement in the treatment of cardiac atrial fibrillation in China [1][2]. Group 1: Product Development and Technology - The StarTrek system is the first open three-dimensional mapping platform in China based on dielectric imaging technology, enhancing the technical level in the field of cardiac atrial fibrillation treatment [1]. - The system operates like a horizontal white computer host, integrating multi-channel mapping and ablation catheter interfaces, and processes electrocardiogram signals in real-time, displaying dynamic mapping of myocardial electrical conduction paths [1]. - The platform supports pulse ablation technology, which uses high-frequency pulse electric fields to precisely destroy lesions without damaging normal myocardial cells, improving the efficiency and safety of atrial fibrillation treatment compared to traditional radiofrequency ablation [1]. Group 2: Cost Reduction and Accessibility - The development team has successfully reduced the manufacturing and usage costs of the product, bringing the cost of a single three-dimensional cardiac electrophysiology mapping system down to one-third of imported products, making advanced technology more accessible to the public [2]. - The system is compatible with all brands of pulse and radiofrequency ablation devices on the market, creating an open technological ecosystem [2]. Group 3: Industry Collaboration and Support - The project is a benchmark initiative incubated by the Kunshan Industrial Research Institute and the team of Academician Chen Yazhu from Shanghai Jiao Tong University, benefiting from deep integration of government, industry, academia, and research [2]. - The company has achieved over 20 patents and raised 47 million yuan in equity financing within three years, being recognized as a leading entrepreneurial talent enterprise in Kunshan and Gusu [2]. Group 4: Future Outlook - The company aims to continue focusing on the high-end medical device market for import substitution, leveraging the supportive ecosystem that fosters innovation and development [3].